Micromedex has been around for a long time, first time I saw the reference it was the big red book. In addition the Drug-REAX information and data base system has been added. Searching the data base will allow tracking to find out impact of treatments on items like worker productivity and how drugs overall affect benefit plans for patient care. We have quite a few resources available today on allergic reactions, etc. but this is the first with the MarketScan data base where I have seen such items mentioned above connected.
I talk about data bases being combined with different companies, their subsidiaries all the time as an awareness item so readers know where the analytics come from and there’s a lot more intelligence out there than you might think. In addition the normal comparisons of generic to name brand drugs is here and the effects on copayments too. I also noticed on the site that as of June all users will need to upgrade to the latest version of Micromedex as the old one seems to be going away at that time. BD
U.S.A., Feb 01, 2011 (Thomson Reuters ONE via COMTEX) --
Ann Arbor, MI, February 1, 2011 - Thomson Reuters announced today that it has launched The Center for Comparative Effectiveness Research to help advance the quality and effective use of comparative effectiveness research (CER) in the U.S. healthcare system.
Comparative effectiveness research evaluates medical treatments to determine which work best in real-world settings. To do this, researchers must assess a comprehensive array of health-related outcomes for diverse patient populations. With nearly four decades of experience in this arena, Thomson Reuters is uniquely positioned to support CER initiatives with proprietary data, experienced researchers, and clinical decision support tools.
"Thomson Reuters works closely with healthcare payers and providers, manufacturers, scientists, and the federal government to manage and analyze data to guide healthcare decision making," said William D. Marder, PhD, a healthcare economist and senior vice president at Thomson Reuters. "This places us in the forefront of information providers who can help the healthcare community apply comparative effectiveness research to improve everyday clinical practice."
The new center will draw on unique information assets including the Thomson Reuters MarketScan(R) Research Databases and clinical data repositories, built for research scientists in the life sciences and for hospital pharmacists. The Thomson Reuters MarketScan databases house integrated patient-level data for populations covered by commercial insurance, Medicaid, and Medicare supplemental plans. This information includes inpatient, outpatient, drug, laboratory, and other data reflecting real-world treatment patterns and costs.
"We have an interdisciplinary team including health services researchers, clinicians, economists, sociologists, and psychologists, many of whom conduct CER analyses," Marder continued. "It seemed natural to develop The Center for Comparative Effectiveness Research to further help our customers address their CER goals and contribute to advancing the national agenda."
Visit The Center for Comparative Effectiveness Research at: http://www.thomsonreuterscer.com.